Abstract:Background Alport syndrome is a genetic disorder characterized by a defective glomerular basement membrane, tubulointerstitial fibrosis, inflammation, and progressive renal failure. IL-11 was recently implicated in fibrotic kidney disease, but its role in Alport syndrome is unknown. Methods We determined IL-11 expression by molecular analyses and in an Alport syndrome mouse model. We assessed the effects of a neutralizing IL-11 antibody (×203) versus an IgG control in Col4a3 −/− mice (lacking the gene encoding a type IV collagen component) on renal tubule damage, function, fibrosis, and inflammation. Effects of ×203, the IgG control, an angiotensin-converting enzyme (ACE) inhibitor (ramipril), or ramipril+X203 on lifespan were also studied. Results In Col4a3 −/− mice, as kidney failure advanced, renal IL-11 levels increased, and IL-11 expression localized to tubular epithelial cells. The IL-11 receptor (IL-11RA1) is expressed in tubular epithelial cells and podocytes and is upregulated in tubular epithelial cells of Col4a3 −/− mice. Administration of ×203 reduced albuminuria, improved renal function, and preserved podocyte numbers and levels of key podocyte proteins that are reduced in Col4a3 −/− mice; these effects were accompanied by reduced fibrosis and inflammation, attenuation of epithelial-to-mesenchymal transition, and increased expression of regenerative markers. X203 attenuated pathogenic ERK and STAT3 pathways, which were activated in Col4a3 −/− mice. The median lifespan of Col4a3 −/− mice was prolonged 22% by ramipril, 44% with ×203, and 99% with ramipril+X203. Conclusions In an Alport syndrome mouse model, renal IL-11 is upregulated, and neutralization of IL-11 reduces epithelial-to-mesenchymal transition, fibrosis, and inflammation while improving renal function. Anti-IL-11 combined with ACE inhibition synergistically extends lifespan. This suggests that a therapeutic approach targeting IL-11 holds promise for progressive kidney disease in Alport syndrome. Significance Statement Alport syndrome (AS), a genetic disorder of the glomerular basement membrane, frequently leads to end stage renal failure. In an animal model of AS—mice lacking the Col4a3 gene, —angiotensin-converting enzyme inhibition is protective. The authors show that IL-11 is upregulated in the renal tubular epithelia of Col4a3 −/− mice; the IL-11 receptor (IL11RA1), expressed on podocytes and tubule cells, is upregulated in the diseased kidneys of Col4a3 −/− mice. Giving 6-week-old Col4a3 −/− mice a neutralizing IL-11 antibody (X203) reduced pathologic ERK and STAT3 activation and limited epithelial-to-mesenchymal transition; reduced kidney fibrosis, inflammation, and tubule damage; and improved kidney function. The median lifespan of Col4a3 −/− mice was prolonged 22% by ramipril alone, 44% with X203 alone, and 99% with ramipril+X203. These data suggest that anti-IL-11 therapies hold promise for treating kidney disease in AS. Visual

Novel Therapies for Alport Syndrome

Exploration of Gene Therapy for Alport Syndrome

Pharmacological approach and diagnosis for Alport syndrome

Alport syndrome: Expanding diagnosis and treatment

Advances and Unmet Needs in Genetic, Basic and Clinical Science in Alport Syndrome: Report from the 2015 International Workshop on Alport Syndrome.

Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children

Renal, Auricular, and Ocular Outcomes of Alport Syndrome and Their Current Management

Stem Cell Therapy for Alport Syndrome: the Hope Beyond the Hype

Dissecting the genotype-phenotype correlation of <i>COL4A5</i> gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome

Genotype-Phenotype Correlations for Pathogenic COL4A3–COL4A5 Variants in X-Linked, Autosomal Recessive, and Autosomal Dominant Alport Syndrome

Establishment of Microrna, Transcript and Protein Regulatory Networks in Alport Syndrome Induced Pluripotent Stem Cells

Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy.

A review of clinical characteristics and genetic backgrounds in Alport syndrome

Genetic Reprogramming with Stem Cells Regenerates Glomerular Epithelial Podocytes in Alport Syndrome

Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome

Genotype–phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome

A comprehensive review of Alport syndrome: definition, pathophysiology, clinical manifestations, and diagnostic considerations

Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice

Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative

A Neutralizing IL-11 Antibody Improves Renal Function and Increases Lifespan in a Mouse Model of Alport Syndrome

The challenges and views in precise diagnosis and treatment of Alport syndrome